Today, we are still unable to predict which one of our patients with a Fontan circulation will succumb or suffer from severe complications. It is estimated that only 61% of patients will survive to age 50, Reference Dennis, Zannino and du Plessis1 and the literature reports that heart transplantation, plastic bronchitis and protein-losing enteropathy may be experienced by up to 4, 14, and 24% of patients, respectively, in the years following Fontan. Reference Dennis, Zannino and du Plessis1–Reference Feldt, Driscoll and Offord3 Yet, in a recent study in Australia and New Zealand, one-third of deceased patients were found to have had a follow-up visit within 2 years of their demise without any report of clinical deterioration in that time. Reference Poh, Hornung and Celermajer4 We still struggle to identify the optimal time at which we should refer patients for heart transplantation. And, at the time when the outcomes of protein-losing enteropathy have vastly improved, we are still unable to distinguish those patients who will have a sustainable recovery and for those whom protein-losing enteropathy is the sign of an unremittable deterioration.
Our difficulty in assessing the clinical status of our patients with Fontan circulation stems from our inability to objectively assess the “Health” of a Fontan circulation. Today we base our judgments on peripheral indices of health such as the exercise capacity, the amount of liver fibrosis, and the severity of the reported symptoms of right-sided heart failure such as decreased exercise capacity, ascites, and peripheral oedema. The main objective measure at our disposal, the measurement of the pressure in the Fontan circulation, in the superior vena cava or the pulmonary arteries, seems to elude its potential to guide us as it largely fails to correlate with adverse outcomes. Reference Rychik, Goldberg and Rand5
We, therefore, reviewed the current literature to assess the relationship of resting Fontan pressure with outcomes related to Fontan failure. Additionally, we explored the relationship between dynamic Fontan pressure measurement and outcomes.
Materials and methods
The PubMed database was used to search for appropriate articles pertaining to the relationship between (1) measurements of elevated resting systemic pressures obtained after a Fontan completion and Fontan failure and (2) exercise or volume load on systemic pressure measurements in patients with Fontan circulation. Systemic pressures were defined as central venous pressure or pulmonary artery pressure. Fontan failure was identified as death, transplantation, protein-losing enteropathy, plastic bronchitis, or Fontan-associated liver disease. Studies were considered eligible if they showed an analysis between post-operative resting central venous pressure or pulmonary artery pressure and markers of Fontan failure or between exercise or volume load on the heart and measured central venous pressure or pulmonary artery pressure following a Fontan operation. A full list of search terms can be found in Supplementary Table S1. Additional articles were identified in our review and were screened for inclusion. All articles from 1976 to January 2023 were included. Non-human and non-English articles were excluded. Articles were excluded if subjects had not reached Fontan completion. Case reports and review papers were also excluded.
Results
An initial search in PubMed produced 431 articles, with an additional 10 identified through references cited in the original search, giving a total of 441 articles to be reviewed for eligibility (Fig. 1). Of those that mentioned Fontan failure, 44 studies identified a relationship between post-Fontan resting systemic pressures and events related to Fontan failure, however, only 26 produced an analysis and were included in the final review. All but 2 Reference Bradley, Jassal, Moore-Clingenpeel, Abraham, Berman and Daniels6,Reference Nakatsuka, Soroida and Nakagawa7 of the 26 studies that presented an analysis between systemic venous pressure and Fontan failure were retrospective (Table 1). Only 10 articles correlated exercise or volume loading to outcomes.
BVR = biventricular repair; CMR = cardiac magnetic resonance; CPET = cardiopulmonary exercise test; CT = computed tomography; CVP = central venous pressure; FALD = Fontan-associated liver disease; Htx = heart transplantation; NYHA-FIII = New York heart association functional class, PAP = pulmonary artery pressure, PLE = protein-losing enteropathy; PB = plastic bronchitis; P = prospective; R = retrospective.
Elevated central venous pressure/pulmonary artery pressure and risk of mortality or heart transplantation
Nine studies Reference Bradley, Jassal, Moore-Clingenpeel, Abraham, Berman and Daniels6,Reference Myers, Waldhausen and Weber8–Reference Rodriguez, Mao and Mahle14 examined the relationship between elevated central venous pressure or pulmonary artery pressure and death or transplantation with only three clearly identifying that elevated pressures were predictive of premature death Reference Ohuchi, Miyazaki and Negishi12,Reference Sethasathien, Silvilairat and Kraikruan13,Reference Inai, Inuzuka and Ono15 and only one showing that higher pulmonary artery pressure was predictive of need for heart transplantation. Reference Bradley, Jassal, Moore-Clingenpeel, Abraham, Berman and Daniels6
In 2017, Ohuchi et al were the first to show the predictive impact of higher central venous pressure on outcomes when measured early (6 months to 5 years post-Fontan), and late (≥ 15 years post-Fontan). Univariate analysis showed an increased risk of late mortality for every 1 mm Hg increase in central venous pressure in the group investigated early (hazard ratio of 1.46, p < 0.001) as well as investigated late (hazard ratio of 1.38, p = 0.0002). Reference Ohuchi, Miyazaki and Negishi12 Subsequently, Sethasathien et al used multivariate cox regression to show that early post-operative elevated pulmonary artery pressure ≥ 23 mm Hg were predictive of mortality within 30 days of Fontan operation (hazard ratio of 23.2, p = 0.004). Reference Sethasathien, Silvilairat and Kraikruan13 More recently, Inai et al performed a multi-institutional study involving nine centres in Japan and found that central venous pressure ≥ 16 mm Hg, measured a median of one year after Fontan completion, was an independent predictor of death in the following 2 decades (hazard ratio of 2.3, p = 0.003). Reference Inai, Inuzuka and Ono15 The only study to find a predictive relationship between elevated central venous pressure and heart transplantation was performed by Bradley et al in 2019. This group looked at six patients with clinical deterioration who were hospitalised at least once for acutely decompensated heart failure and who had a CardioMEMS™ (Abbot, Chicago, IL, US), an implantable hemodynamic monitor inserted. They found that having higher mean pulmonary artery pressure was associated with greater odds of developing a heart failure-mediated event (odds ratio of 1.17, p < 0.0001). Reference Bradley, Jassal, Moore-Clingenpeel, Abraham, Berman and Daniels6 This article also assessed changes in PAP during 10 one-minute exercise intervals and identified a great variability in the changes observed with exercise. Having variations greater than 4 mm Hg was predictive of worse outcomes. Reference Bradley, Jassal, Moore-Clingenpeel, Abraham, Berman and Daniels6
Another two studies pointed to better outcomes in patients with lower central venous pressure. Reference Ohuchi, Ono and Tanabe10,Reference Mori, Hebson and Shioda11 In a group of 60 patients catheterised two decades after Fontan, Mori et al found a slightly higher central venous pressure in those who subsequently died or were transplanted, but time-related analysis could not identify any correlation. Reference Mori, Hebson and Shioda11 In 2012, Ohuchi et al tried to define the characteristics of patients who were in “excellent” condition, defined as not having a re-hospitalization or adverse hemodynamics. The group of patients with excellent status had lower central venous pressure over serial catheterisation performed at 1, 5, 10, and 15 years, but the average of those differences was around 1–2 mm Hg and they considered having a central venous pressure over 16 mmHg to be adverse hemodynamics, precluding any predictive analysis. Reference Ohuchi, Ono and Tanabe10
Another indirect evidence of the lack of adequacy of measuring central venous pressure as an index of the health of the Fontan circulation is brought by a study by Mitchell et al who assessed the hemodynamics of patients before and after heart transplantation. Reference Mitchell, Campbell and Ivy9 This work revealed that, in patients undergoing heart transplantation for late Fontan failure, the pulmonary vascular resistance is elevated above normal, but this fact could only be unveiled early after transplantation as the transpulmonary gradient increased by 8 mmHg early after transplantation (p = 0.0004 by paired analysis). Interestingly, the average PA pressure pre-transplantation was 17 mm Hg. Reference Mitchell, Campbell and Ivy9 On the other hand, Rodriguez et al revealed that mean central venous pressure decreased significantly by 9 mm Hg post-transplantation (p < 0.004). Reference Rodriguez, Mao and Mahle14
Finally, of the nine studies reviewed, the first article to examine relationships between systemic pressure and death was performed in 1990 by Myers et al. Reference Myers, Waldhausen and Weber8 This study, however, found no significance between post-operative mean pulmonary artery pressure in survivors and non-survivors.
Elevated central venous pressure/pulmonary artery pressure and protein-losing enteropathy
Of the 6 Reference Feldt, Driscoll and Offord3,Reference Ohuchi, Yasuda and Miyazaki16–Reference Lin, Fanjiang and Wang20 studies that analysed relationships between central venous pressure or pulmonary artery pressure and protein-losing enteropathy, only one positively identified elevated central venous pressure to be a risk factor for developing protein-losing enteropathy. Reference Ohuchi, Yasuda and Miyazaki16
In a series of 26 patients with protein-losing enteropathy out of a cohort of 354 patients, Ohuchi et al demonstrated that central venous pressure measured one year post-operatively was an independent predictor of developing protein-losing enteropathy, with a 39 times greater risk of developing protein-losing enteropathy if central venous pressure was ≥ 12 mm Hg (Odds ratio of 3.49, p = 0.003). Reference Ohuchi, Yasuda and Miyazaki16
Contrastingly, a historical series was performed by the Mayo Clinic in 1996, where Feldt et al compared 42 patients developing protein-losing enteropathy to the remaining 385 patients of their cohort. Reference Feldt, Driscoll and Offord3 Central venous pressure was measured at serial intervals after Fontan completion but was not a predictor of having protein-losing enteropathy when analysed as a continuous variable. The average pressure of those having protein-losing enteropathy was 19 mm Hg at the time of diagnosis. Reference Feldt, Driscoll and Offord3
The remaining studies observed elevated systemic pressures in patients who were already diagnosed with protein-losing enteropathy. In a series of 42 patients from the Mayo Clinic, John et al analyzed the impact of having a pressure above or below 15 mm Hg at the time of diagnosis of protein-losing enteropathy and demonstrated that patients with pressures < 15 mm Hg had greater survival (p = 0.03). Reference John, Johnson, Khan, Driscoll, Warnes and Cetta17 Ono et al found no difference in mean post-operative central venous pressure between patients with protein-losing enteropathy who underwent Fontan versus biventricular repair (p = 0.47). Reference Ono, Kasnar-Samprec and Hager18 In a seminal multi-centric study of 114 patients, Mertens et al identified that the mean PA pressure at the time of diagnosis of protein-losing enteropathy was 16 mm Hg, Reference Mertens, Hagler, Sauer, Somerville and Gewillig19 and in another smaller study of 6 patients with protein-losing enteropathy, the mean PA pressure was 22 mm Hg at diagnosis. Reference Lin, Fanjiang and Wang20 No correlations were presented in the latter two studies.
Effects of elevated central venous pressure/pulmonary artery pressure and plastic bronchitis
One study examined the central venous pressure in patients with plastic bronchitis and reported that their median pressure within the Fontan baffle was 16 mm Hg (Range 10–28). Reference Avitabile, Leonard and Zemel21 This study only consisted of 14 patients diagnosed with plastic bronchitis, 13 of which had a Fontan completion, and thus no correlations were reported in the results.
Elevated central venous pressure/pulmonary artery pressure and Fontan-associated liver disease
Of the 10 articles Reference Nakatsuka, Soroida and Nakagawa7,Reference Song, Kim and Huh22–Reference Inuzuka, Nii and Inai30 that identified a relationship between elevated systemic venous pressures and symptoms related to liver failure, only two Reference Hansen, Dendale and Coninx29,Reference Inuzuka, Nii and Inai30 showed a predictive relationship.
At a median follow up of 10.2 years post-Fontan, Hansen et al reviewed the relationship of pulmonary artery pressure and liver disease score and found that both times since Fontan (odds ratio of 1.2, p < 0.01) and higher central venous pressure (odds ratio of 1.6, p < 0.001) were predictors of advanced Fontan-associated liver disease. Reference Hansen, Dendale and Coninx29 Inuzuka et al reviewed data from 1117 perioperative survivors of Fontan across nine institutions in Japan with and without Fontan-associated liver disease. Reference Inuzuka, Nii and Inai30 Central venous pressure, measured at an average of one year after Fontan completion, was significantly higher in the Fontan-associated liver disease group (p = 0.011). By Cox regression, higher central venous pressure (by 3 mm Hg increases) was an independent predictor of Fontan-associated liver disease (hazard ratio of 1.28, p = 0.042). Reference Inuzuka, Nii and Inai30 Three additional studies, however, revealed that systemic venous pressures were not predictive of Fontan-associated liver disease, although pressures measured in these studies were no higher than 15 mm Hg Reference Oka, Miyamoto, Tomoyasu, Hayashi and Miyaji24,Reference Patel, Kamande and Jarosz25,Reference Sethasathien, Silvilairat, Sittiwangkul, Makonkawkeyoon and Pongprot28
Additional contrasting evidence was reported in two different studies performed by Schleiger and colleagues. This group initially described the incidence and severity of Fontan-associated liver disease. First, they looked at 21 patients with Fontan failure compared to 108 patients without failure and found that those with higher pulmonary artery pressure had advanced Fontan-associated liver disease (p = 0.006). Reference Schleiger, Kramer and Salzmann26 In a subsequent study, they found that pulmonary artery pressure was significantly higher in patients with liver cirrhosis (p = 0.08), but that it was no longer associated with incidence of Fontan-associated liver disease. Reference Schleiger, Salzmann and Kramer27
The three Reference Nakatsuka, Soroida and Nakagawa7,Reference Song, Kim and Huh22,Reference de Lange, Reichert and Pagano23 remaining studies that assessed systemic venous pressures and liver failure used imaging and biomarkers that were indicative of liver fibrosis and disease, however, all three studies showed no significant associations between central venous pressure and pulmonary artery pressure and liver dysfunction.
Exercise and central venous pressure/pulmonary artery pressure
Two retrospectives Reference Asagai, Inai, Shimada, Harada and Sugiyama31,Reference Egbe, Miranda, Anderson and Borlaug32 and three prospective studies Reference Goldstein, Connor, Gooding and Rocchini33–Reference Claessen, La Gerche and Van De Bruaene35 were included (Table 2).
CO = cardiac output; CVP = central venous pressure; PAP = pulmonary artery pressure; P = prospective; R = retrospective; SVPs = systemic venous pressures; W = watts.
All of the studies that were reviewed looked at central venous pressure or pulmonary artery pressure measurements during various exercise stress tests. In an earlier study, Goldstein et al. measured pulmonary artery pressure during exercise in the supine position and found that it increased significantly in six patients with Fontan circulation. Mean pulmonary artery pressure increased from 16 mm Hg at rest to 25 mm Hg at peak exercise (p = 0.001). Reference Goldstein, Connor, Gooding and Rocchini33 Another study by Claessen et al measured mean pulmonary artery pressure during supine ergometer exercises in healthy controls versus patients with Fontan circulation. Mean pulmonary artery pressure was higher in the control groups at baseline and during exercise. The mean PA pressure in patients with a Fontan increased from 9 to 21 mm Hg. Reference Claessen, La Gerche and Van De Bruaene35 Most notably, Navaratnam et al. showed in the initial figure of their manuscript that there is a wide variation in systemic venous pressures between controls and patients with a Fontan circulation with even a minimal amount of exercise. Reference Navaratnam, Fitzsimmons and Grocott34 Exercise in this study consisted of patients completing 8–12 minutes on an electromagnetically braked bicycle. In patients with normal biventricular circulation, there was an increase in central venous pressure of 5–10 mmHg with exercise while these elevations were significantly more pronounced in patients with Fontan circulation. The slope of increase in venous pressure from even a minimal amount of exercise varied greatly in the small set of patients that were tested, with some of the patients having central venous pressure increasing to a level up to 35 mmHg. Reference Navaratnam, Fitzsimmons and Grocott34 (Fig. 2) A retrospective study by Asagai et al examined central venous pressure changes before and during hand ergometer exercises. They also found great variations between patients in terms of the size of increase of PA pressures at exercise and identified some correlation between having an elevated PA pressure on exercise and some biological parameters. Reference Asagai, Inai, Shimada, Harada and Sugiyama31 In a detailed analysis of hemodynamic parameters during exercise in 29 symptomatic patients with Fontan circulation, Egbe et al determined that a constructed “vascular reserve index,” extracted from the change during exercise in the ratio between pulmonary artery pressures and cardiac output, was able to better define pulmonary vascular function. They found that pulmonary vascular reserve was impaired in these patients during exercise, even when patients had a normal vascular resistance at baseline, and that these limitations in reserve during exercise were associated with end-organ dysfunction. Thus, this index might be best used to assess the health of the pulmonary vascular bed and to prevent the eventual end-organ damage of patients with a Fontan circulation. Reference Egbe, Miranda, Anderson and Borlaug32
Volume loading and central venous pressure/pulmonary artery pressure
Four prospective studies Reference De Mey, Cools and Heying36–Reference Möller, Klungerbo and Diab39 and one retrospective study Reference Peck, Averin and Khoury40 investigating the impact of volume loading on central venous pressure measurements were found. (Table 3) In 2015, the team from Leuven studied 28 patients with Fontan circulation having 32 catheterisation studies. They showed a significant difference (p < 0.05) in mean venous pressure before (14.6 ± 2.8 mm Hg, Range 10–21) and after intravascular volume loading of 15cc/Kg of 0.9% NaCl (18.3 ± 3.3 mm Hg, Range 2–19), with clear variation in individual responses to the volume challenge. They concluded that pressure changes in response to volume increases can be helpful in differentiating between cardiac and pulmonary limitations. Reference De Mey, Cools and Heying36 A similar study by Möller et al. found a significant increase in mean central venous pressure following rapid volume expansion (5 mL of 0.9% saline/kg of body weight at room temperature) (p < 0.001) and this study also illustrated variable slopes in patients’ pressure responses to volume expansion. Reference Möller, Klungerbo and Diab39
BVR = biventricular repair; CVP = central venous pressure; EDP = end-diastolic pressure; MVP = mean venous pressure; ODD = occult diastolic dysfunction; P = prospective; RVE = rapid volume expansion; R = retrospective; VAD = ventricular assist device.
One hospital in particular has implemented a ventricular stress test protocol using rapid volume expansion as part of standard clinical care in patients undergoing cardiac catheterisation. In their initial reports following this implemented protocol, Averin et al found that mean Fontan circuit pressure, as well as ventricular end-diastolic pressure, increases significantly following ventricular volume load (15 mL/kg of 0.9% NaCl). Mean pressures increased from 12.4 ± 2.2 mm Hg at rest to 15.2 ± 2.5 (p < 0.001) following volume loading. When looking closely at the slopes of the ventricular end-diastolic pressure in each patient, those who initially had a systemic ventricle end-diastolic pressure less than 15 mm Hg that increased above 15 mm Hg after volume loading were labelled as having occult diastolic dysfunction. Reference Averin, Hirsch, Seckeler, Whiteside, Beekman and Goldstein37 This group later reviewed 28 patients with occult diastolic dysfunction and 61 without occult diastolic dysfunction and demonstrated that occult diastolic dysfunction was associated with late adverse outcomes related to Fontan failure (Fig. 3). Interestingly, central venous pressure pressures at baseline were not different in those with or without occult diastolic dysfunction. Reference Peck, Averin and Khoury40
A Japanese study demonstrated that in response to volume load by angiography (0.4 mg/kg of indocyanine green contrast medium), central venous pressure increased more in patients with a Fontan circulation than in patients with a biventricular circulation (10.2 ± 3.1 mm Hg versus 6.2 ± 3.4 mm Hg, p < 0.0001). Reference Kim, McSweeney, Lee and Ivy38
Discussion
Fifty years after the description of the Fontan operation, there seem to be only 26 studies that closely investigate the relationship between elevated resting central venous or pulmonary pressures after Fontan completion and adverse outcomes. Of those, seven Reference Bradley, Jassal, Moore-Clingenpeel, Abraham, Berman and Daniels6,Reference Ohuchi, Miyazaki and Negishi12,Reference Sethasathien, Silvilairat and Kraikruan13,Reference Inai, Inuzuka and Ono15,Reference Ohuchi, Yasuda and Miyazaki16,Reference Hansen, Dendale and Coninx29,Reference Inuzuka, Nii and Inai30 articles showed the predictive impact of elevated venous pressures on Fontan failure, five Reference Feldt, Driscoll and Offord3,Reference Mori, Hebson and Shioda11,Reference Oka, Miyamoto, Tomoyasu, Hayashi and Miyaji24,Reference Patel, Kamande and Jarosz25,Reference Sethasathien, Silvilairat, Sittiwangkul, Makonkawkeyoon and Pongprot28 showed no predictive impact, and another 14 Reference Nakatsuka, Soroida and Nakagawa7–Reference Ohuchi, Ono and Tanabe10,Reference Rodriguez, Mao and Mahle14,Reference John, Johnson, Khan, Driscoll, Warnes and Cetta17–Reference de Lange, Reichert and Pagano23,Reference Schleiger, Kramer and Salzmann26,Reference Schleiger, Salzmann and Kramer27 looked at the relationships between variables, with only 5 Reference Ohuchi, Ono and Tanabe10,Reference Rodriguez, Mao and Mahle14,Reference John, Johnson, Khan, Driscoll, Warnes and Cetta17,Reference Schleiger, Kramer and Salzmann26,Reference Schleiger, Salzmann and Kramer27 of those showing a significant association. Only two studies Reference Sethasathien, Silvilairat and Kraikruan13,Reference Inai, Inuzuka and Ono15 showing a positive relationship between elevated pressures and mortality could identify a cut-off value that would be of clinical relevance. Inai et al found that central venous pressure ≥ 16 mm Hg was an independent predictor of death, but only in patients with a median follow-up time of 1 year. Reference Inai, Inuzuka and Ono15 Sethasathien et al found that a mean pulmonary artery pressure ≥ 23 mm Hg is predictive of mortality, but this was measured within 30 days of Fontan operation. Reference Sethasathien, Silvilairat and Kraikruan13 Ohuchi et al identified a cut-off value of 12 mm Hg to predict 3 times increased risk of protein-losing enteropathy. Reference Ohuchi, Yasuda and Miyazaki16 That value may not be discriminant enough for us to neither make predictions nor change treatment course, as there is a subset of our healthy asymptomatic patients that are reported to have values above this cut-off. Reference Miranda, Hagler, Connolly, Kamath and Egbe41 Another study showed that patients with protein-losing enteropathy who had PA pressures above 15 mm Hg had a higher risk of late death. Reference John, Johnson, Khan, Driscoll, Warnes and Cetta17 The pressure cut-off values in all other studies showing a positive association were only analysed as continuous variables. With nine studies Reference Bradley, Jassal, Moore-Clingenpeel, Abraham, Berman and Daniels6,Reference Ohuchi, Ono and Tanabe10,Reference Rodriguez, Mao and Mahle14,Reference Ohuchi, Yasuda and Miyazaki16,Reference John, Johnson, Khan, Driscoll, Warnes and Cetta17,Reference Schleiger, Kramer and Salzmann26,Reference Schleiger, Salzmann and Kramer27,Reference Hansen, Dendale and Coninx29,Reference Inuzuka, Nii and Inai30 showing significantly higher central venous pressure pressures in patients with worse outcomes, it is undeniable that the central venous and pulmonary pressures of our patients will rise during failure of the Fontan circulation. There are multiple possible reasons for these observations, for example, vasoplegia related to anaesthesia, hypovolemia induced by fasting, the supine position and changes induced by medications may all explain what is happening during this phenomenon.
Despite our need to have an objective way to assess the health of the Fontan circulation of our patients, the most significant value collected is providing us only a vague impression rather than a clear indication of a pathological phenomenon. It has been postulated that dynamic testing of these pressures under exercise condition or with bolus of volume testing may be more sensitive to detect patients with early stages of the failure of the Fontan circulation. The seven studies investigating this hypothesis seem to point to a great variation in the slope of increase of these central pressures under these conditions. We suspect that patients with a steeper slope of increase in systemic pressure will correlate with worst function of the Fontan circulation. No studies have yet been able to clearly identify a relationship betwen this steeper slope of increase and subsequent adverse outcomes and should be addressed in future work.
Continuous monitoring of these pressures may ultimately be useful in the future but remain fraught with technical difficulties at this stage. Reference Bradley, Jassal, Moore-Clingenpeel, Abraham, Berman and Daniels6,Reference Salavitabar, Bradley and Chisolm42,Reference Parekh and Krajcer43 Other non-invasive continuous monitoring devices that measure peripheral venous pressures have been introduced, but only a few studies have actually shown that these pressures are comparable to central venous pressure or pulmonary artery pressure. Reference Colman, Alsaied and Lubert44,Reference Tan, Small, Gallotti, Moore and Aboulhosn45
While we are limited by the number of studies that are reported on this topic, and by the low yield of patients that are reported on in these few studies, it is important to highlight the need to report more results on this topic. In this regard, the articles presented in this review vary dramatically in the number of patients analysed, and therefore it may be unfair to compare significant predictions made from articles with thousands of patients to nonsignificant results from smaller population samples. It is also important to note that in reporting on resting systemic venous pressures, there are many factors that are confounding the associations between systemic pressure and adverse outcomes. General anaesthesia during cardiac catheterisation, for example, interferes with the hemodynamics of the patient and will be responsible for an underestimate of the pressures of these patients. Reference Lin, Desai and Nicolas46,Reference Williams, Jones, Hanson and Morray47 These patients usually arrive volume depleted after fasting since at least the previous night, which will affect the hemodynamics measured during catheterizations. The concomitant use of contrast agents and medications will also interfere with the measurement of these resting pressures.
In conclusion, while it has been shown in some studies that Fontan failure is associated with elevation of the central venous pressure, the observed resting catheterisation measurements in the literature fail to provide us with useful cut-off values above which long-term adverse outcomes could be predicted. Current studies showing central venous pressure or pulmonary artery pressure changes during exercise or volume loading identify a vast array of differences in the slopes of venous pressure changes between patients. Further studies are needed to prospectively investigate whether more dynamic measurement of central venous pressure and pulmonary artery pressure in patients with a Fontan circulation would allow us to better identify the health status of these patients and better predict their outcomes. These novel investigations could potentially unmask the patients who have occult diastolic dysfunction or increasing pulmonary vascular resistance, identify patients who will have a worse outcome after an episode of protein-losing enteropathy, and may better delineate at what stage a patient should be introduced to more intensive heart failure medications or even heart transplantation.
Supplementary material
The supplementary material for this article can be found at https://doi.org/10.1017/S1047951123003797.
Acknowledgements
We would like to thank the publishers of Navaratnam et al (Elsevier) and Peck et al (Wiley Blackwell) for allowing us to use their figures in our work.
Financial support
This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.
Competing interests
None.